| Primary Identifier | MGI:4947569 | Allele Type | Transgenic |
| Attribute String | Inducible, Recombinase | Gene | Et(icre/ERT2)14208Rdav |
| Strain of Origin | C57BL/6J | Induced With | tamoxifen |
| Is Recombinase | true | Is Wild Type | false |
| Project Collection | Neuroscience Blueprint cre |
| molecularNote | An enhancer trap lentiviral transgenic approach was used to generate these mice. The transgene was designed with a self-inactivating lentiviral vector backbone (FUGW), a human synapsin minimal promoter (-244 to +47), a beta-globin intron, an icre /ERT2 fusion (icre; improved with mammalian codon usage, no putative cryptic splice sites, altered stop codon, and reduced CpG content to limit the chances of epigenetic silencing in mammals), fused to a mutated human estrogen receptorligand binding domain (ERT2), and a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE; to enhance the mRNA transcript stability. This packaged lentivirus was injected subzonally (under the zona pellucida) into 1-2 cell stage C57BL/6J mouse embryos. Founders were crossed to C57BL/6 animals. Animals were crossed to B6-Gt(ROSA)26Sortm1Sor mice to assess cre activity/transmission. Cre positive, lacZ negative mice were subsequently bred to C57BL/6 mice to create the 14208 line. |
